Immunovant, Inc.
$31.15
+1.2%Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -11.3).
Valuation inputs: P/E -11.3, earnings yield N/A, momentum +1.2%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -59.3%, ROIC 0.0%).
Profitability stack: net margin 0.0%, ROE -59.3%, ROIC 0.0%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +10.9%, momentum +1.2%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Immunovant, Inc. Market vs Earnings Trajectory
Performance Analysis
EPS Growth
Positive earnings growth shows the company is improving its profitability over time.
Price-EPS Relationship
Stock price is moving in line with earnings growth—a healthy sign of fundamental-driven valuation.
Stock Price Change
Over the 1Y period, stock price has increased by 103.1%.
P/E Ratio (TTM)
Relatively low P/E may indicate undervaluation or lower growth expectations.
Key Insight
With growing earnings (+5.6%) and a relatively low P/E ratio (-11.3x), the stock may be undervalued if the growth trend continues.
Immunovant, Inc. Fair Value Envelope
No Revenue Data
IMVT has not reported any revenue values in the available annual periods.
Immunovant, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
IMVT has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
IMVT has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
IMVT has not reported any net profit margin values in the available annual periods.
Immunovant, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Declining FCF warrants attention. Investigate whether due to temporary factors or fundamental deterioration.
Working Capital Impact
Neutral working capital impact. Changes in current assets and liabilities balanced out.
Immunovant, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Immunovant, Inc. Street Expectations Map
Wall Street analysts project that IMVT stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 43.67, with estimates ranging from a low of 40.00 to a high of 50.00.
The consensus 1-year price target stands at 43.67, with estimates ranging from a low of 40.00 to a high of 50.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Immunovant, Inc. Insider Positioning
During the last 12 months, insiders have purchased $350.00M and sold $3.75M worth of IMVT shares, resulting in $346.25M of net buying activity.
3 Months
0
0.00
86.9K
2.43M
-2.4M
-$2.43M
3-6 Months
16.7M
350.00M
13.1K
349.07K
+349.7M
+$349.65M
6-9 Months
0
0.00
37.6K
833.00K
-833K
-$833K
9-12 Months
0
0.00
7.9K
140.38K
-140K
-$140K
Top Buyers
Roivant Sciences Ltd.
Director, 10 Percent Owner:
$350.00M
Top Sellers
Fromkin Andrew J.
Director
$823K
Girao Tiago
Officer: Chief Financial Officer
$763K
Stout Jay S
Officer: Chief Technology Officer
$528K
Gloria Melanie
Officer: Chief Operating Officer
$504K
Van Tuyl Christopher
Officer: Chief Legal Officer
$428K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $346.25M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
No Dividend Yield Data
IMVT has not reported any dividend yield values in the available annual periods.
imvt Dividend History
Learning Layer
Related Guides
Build conviction on IMVT by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.